Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …

Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic
stress directly impact the cardiovascular system. Over the last few years, the contributions of …

Doxorubicin (DOX)-related cardiotoxicity has been recognized as a serious complication of
cancer chemotherapy. Effective targeted strategies for myocardial protection in addition to …

Cardiac injury is the main dose-limiting factor for doxorubicin (Dox) use as an anticancer
agent. The cardiotoxicity of Dox is linked to a number of complex mechanisms, including …

Doxorubicin (DOX) is a highly effective chemotherapeutic drug, but its long-term use can
cause cardiotoxicity and drug resistance. Accumulating evidence demonstrates that p53 is …

The chemotherapeutic drug Doxorubicin is the most commonly prescribed in the world.
However, its clinical wide application is limited due to harmful side effects like cardiotoxicity …

Doxorubicin is a widely used anticancer drug in clinical practice for the treatment of various
human tumors. However, its administration is associated with cardiotoxicity. Administration …

Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated
dose of a cancer drug. In addition to the specific mechanisms of each drug, common …

Nicotinamide adenine dinucleotide (NAD) coenzymes are carriers of high energy electrons
in metabolism and also play critical roles in numerous signaling pathways. NAD metabolism …

Doxorubicin (Dox), an anthracycline antibiotic with potent antitumor effects, has limited
clinical applications due to cumulative cardiotoxicity. Ca2+/calmodulin‐dependent protein …